Cipla is one of India’s most respected pharmaceutical companies, specializing in affordable medicines and life-saving treatments. Founded in 1935, Cipla has played a pioneering role in making essential drugs accessible in India and emerging markets. A Nifty 50 member since 7 October 1998, Cipla’s mission is to ensure “None Shall Be Denied” by producing high-quality, cost-effective pharmaceuticals. The company’s portfolio spans respiratory, oncology, HIV/AIDS, and critical care therapies, supplying both generics and branded medicines across 80+ countries. Its innovation focus lies in inhalation devices, complex generics, and biosimilars. Cipla is known for its ethical practices and humanitarian initiatives, especially in making antiretroviral drugs affordable globally. Leveraging strong R&D, manufacturing excellence, and regulatory compliance, Cipla continues to bridge the gap between access and innovation. With a focus on sustainability, patient-centricity, and global partnerships, the company is committed to improving healthcare outcomes worldwide while maintaining a legacy of trust and social impact.